CD Antigen Cancer Therapy Market Size and Forecast 2026-2035
The global CD antigen cancer therapy market is estimated at USD 30.80 billion in 2025 and is forecast to reach USD 93.13 billion by 2035, expanding at a modeled CAGR of 11.7% during 2026-2035.
The wider market is also expanding rapidly outside J&J. Gilead reported USD 1.8 billion in 2025 cell-therapy sales, including USD 1.5 billion for CD19-directed Yescarta and USD 344 million for Tecartus. BMS reported USD 1.4 billion for Breyanzi and USD 427 million for BCMA-directed Abecma, while Genmab reported USD 468 million in global EPKINLY/TEPKINLY sales.
CD Antigen Cancer Therapy Market Highlights
- 2025 Market Size: USD 30.80 Billion
- 2035 Forecast Market Size: USD 93.13 Billion
- CAGR, 2026-2035: 11.7%
- Largest Region: North America - 41.5% modeled share
- Fastest-Growing Region: Asia-Pacific
- Leading Product Type: Monoclonal Antibodies - 56.5% modeled share
- Leading Antigen: CD38 - 48.8% modeled share
- Leading Cancer Type: Multiple Myeloma
CD Antigen Cancer Therapy Market Definition
CD, or cluster of differentiation, antigens are cell-surface molecules used to distinguish immune and hematopoietic cell populations. Malignant cells can retain or overexpress particular surface antigens, creating targets for monoclonal antibodies, antibody-drug conjugates, engineered T cells and bispecific antibodies.
The commercial market includes established targets such as CD19, CD20, CD22, CD30, CD33, CD38 and CD79b, together with BCMA, also designated CD269, in plasma-cell malignancies. The legacy page currently limits its explicit antigen segmentation primarily to CD19, CD20, CD22 and CD30, which no longer captures the commercial structure of the market.
The market is concentrated in hematological malignancies because surface antigens tend to be more lineage-specific and therapeutically accessible in B-cell, plasma-cell and myeloid cancers than in many solid tumors.
White-Space Opportunity: Multi-Antigen Targeting to Reduce Antigen Escape
The next major development phase is moving beyond one antigen at a time.
Single-target therapy can place strong selective pressure on malignant cells. When a cancer loses or downregulates the targeted antigen, previously effective immune therapy may no longer recognize the tumor. This creates a strategic rationale for simultaneously targeting two or three surface antigens.
An NCI-listed Phase III study is now comparing rondecabtagene autoleucel, a dual CD19/CD20 CAR-T therapy, against investigator-selected CD19 CAR-T therapy in second-line relapsed/refractory large B-cell lymphoma.
NCI also lists active development of CD19/CD20/CD22 triple-targeted CAR-T cells in relapsed or refractory non-Hodgkin lymphoma, ALL and CLL.
This creates an important white-space opportunity through 2035. The next generation of cell therapy may compete less on whether CAR-T works and more on whether multi-antigen recognition can prevent target-negative relapse while maintaining acceptable toxicity and manufacturability.
CD Antigen Cancer Therapy Market Strategic Takeaways
The market is shifting from a monoclonal-antibody-dominated structure toward a more diversified ecosystem involving CAR-T, bispecific antibodies and ADCs. Antibodies still dominate revenue because of DARZALEX's extraordinary scale, but faster-growing cellular and bispecific therapies are reducing their percentage share.
CD38 is the largest antigen category because DARZALEX alone produced USD 14.351 billion of 2025 sales, with Sanofi's Sarclisa adding another expanding anti-CD38 franchise. J&J subsequently strengthened CD38's position with additional frontline and combination approvals in 2026.
BCMA/CD269 is developing into the fastest-moving major target ecosystem. It now supports CAR-T products, bispecific CD3 engagers and an ADC. FDA developments during 2025-2026 included Lynozyfic, the return of Blenrep, and the March 2026 approval of Tecvayli plus Darzalex Faspro after at least one prior line of therapy.
CD20 is also entering a second commercial cycle. Rituximab established the target decades ago, but epcoritamab, mosunetuzumab and glofitamab now use CD20 to recruit T cells directly, creating a growing chemotherapy-sparing lymphoma segment.
CD Antigen Cancer Therapy Market Trends
CD38 Has Become a Foundational Multiple Myeloma Target
Anti-CD38 treatment is no longer confined to later-line myeloma.
DARZALEX has progressively moved into frontline combinations and generated USD 14.351 billion in 2025 sales, up 23% from 2024. It represented 15% of Johnson & Johnson's total company revenue.
On January 27, 2026, FDA approved Darzalex Faspro with bortezomib, lenalidomide and dexamethasone for newly diagnosed multiple myeloma in adults ineligible for autologous stem-cell transplantation. The CEPHEUS study reported MRD negativity of 52.3% with the Darzalex-containing regimen versus 34.8% with VRd.
The addressable CD38 market was expanded even further in November 2025 when FDA approved Darzalex Faspro for high-risk smoldering multiple myeloma, pushing antigen-directed treatment into a disease state before conventional active multiple myeloma.
Subcutaneous Delivery Is Becoming a Competitive Advantage
Administration convenience has become a meaningful differentiator among antigen-directed antibodies.
On July 9, 2026, FDA approved Sarclisa Escena, subcutaneous isatuximab delivered using an on-body delivery system, across several multiple-myeloma indications. In IRAKLIA, subcutaneous isatuximab plus pomalidomide and dexamethasone was non-inferior to the intravenous formulation.
Roche's Lunsumio Velo represents the same trend in lymphoma. FDA approved the subcutaneous formulation of the CD20×CD3 bispecific mosunetuzumab for relapsed/refractory follicular lymphoma in December 2025.
As products move into earlier lines, shorter chair time and easier outpatient administration can become commercially important alongside efficacy.
BCMA Is Becoming a Multi-Modality Target
BCMA/CD269 demonstrates how one antigen can support several competing therapeutic technologies.
CARVYKTI and Abecma use CAR-T cells, while Tecvayli, Elrexfio and Lynozyfic redirect T cells with bispecific antibodies. Blenrep uses the same target through an antibody-drug conjugate.
FDA granted accelerated approval to Lynozyfic in July 2025 for heavily pretreated relapsed/refractory multiple myeloma. LINKER-MM1 produced a 70% objective response rate in the FDA efficacy population.
In October 2025, FDA approved Blenrep with bortezomib and dexamethasone, returning BCMA-directed ADC therapy to the U.S. market. DREAMM-7 reported median progression-free survival of 31.3 months versus 10.4 months with daratumumab, bortezomib and dexamethasone, although ocular toxicity requires a REMS program.
The BCMA market therefore increasingly revolves around sequencing and combination, not simply choosing one target.
BCMA and CD38 Are Now Being Combined Directly
On March 5, 2026, FDA approved Tecvayli plus Darzalex Faspro for adults with relapsed/refractory multiple myeloma after at least one prior line containing a proteasome inhibitor and immunomodulatory agent. The same decision converted Tecvayli's original heavily pretreated monotherapy indication from accelerated to traditional approval.
Commercially, this is significant because the market is moving from competition between antigen classes toward simultaneous antigen targeting.
A patient can now receive a BCMA×CD3 bispecific together with a CD38 antibody, dramatically increasing treatment value per eligible patient while also raising infection-management requirements.
CD20 Bispecifics Are Moving Into Earlier Lymphoma Treatment
CD20 was historically synonymous with rituximab and related monoclonal antibodies.
That structure is changing rapidly.
Epcoritamab, mosunetuzumab and glofitamab bind CD20 on malignant B cells while simultaneously engaging CD3-positive T cells. FDA's November 2025 approval of epcoritamab with lenalidomide and rituximab for relapsed/refractory follicular lymphoma was supported by the 488-patient EPCORE FL-1 randomized trial.
Genmab reported USD 468 million in global EPKINLY/TEPKINLY net sales during 2025, up from USD 281 million in 2024.
Roche similarly reported strong growth in Columvi, while its established Polivy CD79b ADC generated CHF 1.47 billion of 2025 sales.
CAR-T Is Expanding Across More B-Cell Lymphoma Subtypes
CD19-directed CAR-T is moving beyond aggressive large B-cell lymphoma.
FDA approved Breyanzi for relapsed/refractory marginal zone lymphoma on December 4, 2025, making it the first CAR-T therapy approved in the United States for MZL. Among treated patients in the supporting study, 95.5% responded and 62.1% achieved a complete response.
BMS reported USD 1.4 billion in Breyanzi revenue during 2025, demonstrating that CD19 CAR-T is already a substantial commercial category rather than an experimental niche.
CD30 and CD79b Keep ADCs Commercially Relevant
ADC development is sometimes overshadowed by CAR-T and bispecifics, but it remains commercially important.
Brentuximab vedotin targets CD30 and remains an established therapy across Hodgkin and selected T-cell lymphomas. Polatuzumab vedotin targets CD79b and is integrated into DLBCL treatment, with Roche reporting CHF 1.47 billion in Polivy sales during 2025, up 38% at constant exchange rates.
BCMA-directed Blenrep's U.S. return adds another major ADC platform, reinforcing the value of delivering cytotoxic payloads selectively through surface antigens.
CD Antigen Cancer Therapy Market Scope
| Metrics | Details |
| Historical Years | 2023-2024 |
| Base Year | 2025 |
| 2025 Market Size | USD 30.80 Billion |
| Forecast Period | 2026-2035 |
| 2035 Market Size | USD 93.13 Billion |
| CAGR | 11.70% |
| Largest Region | North America |
| Fastest-Growing Region | Asia-Pacific |
| Product Type | Monoclonal Antibodies, CAR-T, Bispecific/T-Cell Engagers, ADCs, Others |
| Target Antigen | CD38, CD20, CD19, BCMA/CD269, CD30, CD79b, CD22, CD33, Others |
| Cancer Type | Multiple Myeloma, B-Cell Lymphomas, Leukemias, Hodgkin Lymphoma, Others |
| End User | Hospitals/Cancer Centers, Cell-Therapy Centers, Specialty Clinics, Others |
| North America | U.S., Canada, Mexico |
| Europe | Germany, UK, France, Italy, Spain, Rest of Europe |
| Asia-Pacific | China, Japan, South Korea, India, Australia, Rest of Asia-Pacific |
| Latin America | Brazil, Argentina, Rest of Latin America |
| Middle East & Africa | Saudi Arabia, UAE, Israel, South Africa, Rest of MEA |
CD Antigen Cancer Therapy Market Disruption Analysis
The first disruption is modality convergence. A single surface antigen can now be attacked with conventional antibodies, ADCs, CAR-T cells or bispecific T-cell engagers, creating direct competition among technologies that previously occupied separate treatment categories.
The second disruption is movement into earlier disease. CD38 therapy now extends from active multiple myeloma into high-risk smoldering myeloma, while CAR-T and bispecific programs are moving progressively closer to first relapse.
The third disruption is multi-target therapy. NCI-listed trials of CD19/CD20 and CD19/CD20/CD22 CAR-T products illustrate a broader effort to reduce antigen-negative relapse and increase tumor coverage.
The fourth disruption is decentralization. Subcutaneous bispecifics and anti-CD38 products can reduce infusion requirements, while improvements in CAR-T manufacturing are gradually expanding the number of treatment centers able to offer cellular therapy.
CD Antigen Cancer Therapy Market Dynamics
Large Hematologic Cancer Burden Supports Continued Demand
GLOBOCAN 2024 estimated 562,793 new non-Hodgkin lymphoma cases and 234,903 deaths worldwide, while multiple myeloma accounted for 196,157 new cases and 119,029 deaths.
These diseases account for much of the commercial demand for CD19-, CD20-, CD38-, CD79b, and BCMA-targeted treatment.
In the United States alone, SEER estimates 79,320 new non-Hodgkin lymphoma cases and 19,970 deaths in 2026.
Earlier-Line Use Expands Revenue Per Patient
The principal growth driver is no longer the discovery of completely new antigen targets. It is the movement of established targets into larger patient populations and earlier treatment lines.
DARZALEX illustrates this effect. Its 2025 sales rose 23% to USD 14.351 billion, while new indications continued to extend CD38 therapy into newly diagnosed and pre-myeloma populations.
Bispecific Antibodies Reduce the Manufacturing Barrier of CAR-T
CAR-T can produce deep responses but requires individualized cell collection, manufacturing and infusion.
Off-the-shelf bispecific antibodies activate the patient's own T cells without manufacturing a bespoke cellular product. This creates a substantially different logistics model, although CRS, ICANS, infections and step-up dosing remain important operational considerations. FDA labels for EPKINLY, COLUMVI and BCMA bispecifics continue to contain detailed monitoring requirements.
CAR-T Manufacturing Capacity Remains a Constraint
Cell therapy requires leukapheresis, manufacturing capacity, lymphodepleting chemotherapy and specialized clinical infrastructure.
Despite those constraints, commercial uptake remains strong. CARVYKTI sales nearly doubled to USD 1.887 billion during 2025, while Breyanzi reached USD 1.4 billion.
CRS, Neurotoxicity and Infection Affect Site of Care
T-cell redirecting therapies can produce cytokine release syndrome and neurologic toxicity.
FDA's Lynozyfic approval, for example, includes a boxed warning and REMS for CRS and neurologic toxicity, including ICANS.
The growing use of bispecific combinations can also increase infection risk, meaning commercial expansion depends partly on prophylaxis, monitoring and increasingly manageable outpatient workflows.
CD Antigen Cancer Therapy Segment Analysis
Monoclonal Antibodies Lead with 56.5%
Conventional and engineered monoclonal antibodies are estimated to generate 56.5% of 2025 market revenue, equal to around USD 17.40 billion.
CD38 accounts for most of this value. DARZALEX generated USD 14.351 billion in 2025, while Sarclisa continues to expand through new frontline indications and the July 2026 subcutaneous formulation.
The monoclonal-antibody share is lower than it would have been several years ago because CAR-T and bispecific antibodies are growing faster.
CAR-T Represents 16.4%
CAR-T cell therapies are estimated to account for 16.4% of 2025 market value, or about USD 5.05 billion.
The category includes CD19 products such as Yescarta, Tecartus and Breyanzi and BCMA products such as Carvykti and Abecma.
Commercial evidence supports this scale: Yescarta produced USD 1.5 billion in 2025 sales, Breyanzi USD 1.4 billion, Carvykti USD 1.887 billion, Tecartus USD 344 million and Abecma USD 427 million.
Bispecific/T-Cell Engagers Account for 11.8%
Bispecific and T-cell-engaging antibodies represent an estimated 11.8% of the 2025 market, USD 3.63 billion.
The segment is one of the fastest growing because it spans both CD20 lymphoma therapies and BCMA myeloma therapies.
J&J reported USD 670 million in 2025 Tecvayli revenue, Genmab reported USD 468 million in EPKINLY/TEPKINLY sales, and Roche reported rapid Columvi growth.
Earlier-line combinations such as Tecvayli plus Darzalex should accelerate this category through 2035.
ADCs Represent 10.2%
Antibody-drug conjugates are estimated to contribute 10.2% of global revenue, around USD 3.14 billion.
Important antigen targets include CD30 through Adcetris, CD79b through Polivy and BCMA through Blenrep.
Polivy alone generated CHF 1.47 billion in 2025 sales, while Blenrep's October 2025 U.S. approval re-established an important BCMA ADC franchise.
CD38 Holds 48.8% of Target Revenue
CD38 is estimated to account for 48.8% of the global market in 2025, or around USD 15.03 billion.
DARZALEX is the principal driver and remains one of the world's largest oncology brands. Sarclisa provides growing competition, particularly as its formulation and frontline reach expand.
CD20 Accounts for 17.6%
CD20 represents an estimated 17.6% of market revenue, USD 5.42 billion.
The segment combines mature monoclonal antibodies such as rituximab and obinutuzumab with newer CD20×CD3 bispecifics including epcoritamab, mosunetuzumab and glofitamab.
Roche reported 2025 sales of CHF 962 million for MabThera/Rituxan and CHF 288 million for Columvi, while Genmab reported USD 468 million for EPKINLY/TEPKINLY.
CD19 Represents 15.3%
CD19 is estimated to hold 15.3%, around USD 4.71 billion, and remains the dominant CAR-T target in B-cell malignancies.
Yescarta, Tecartus and Breyanzi account for billions of dollars in annual revenue, while tafasitamab provides a non-cellular CD19-directed antibody approach.
Dual CD19/CD20 and triple CD19/CD20/CD22 programs could change this segment's structure if they demonstrate lower antigen-escape rates.
BCMA/CD269 Represents 10.5%
BCMA/CD269 accounts for an estimated 10.5% of 2025 market revenue, USD 3.23 billion, and is expected to be the fastest-growing large target segment.
CARVYKTI generated USD 1.887 billion in 2025, Tecvayli USD 670 million and Abecma USD 427 million before adding revenue from Elrexfio and emerging Lynozyfic and Blenrep use.
Multiple Myeloma Generates the Largest Disease-Specific Revenue
Multiple myeloma is estimated to contribute 59% of CD antigen cancer therapy revenue in 2025.
This unusually high share reflects the simultaneous commercial scale of CD38 and BCMA therapies. GLOBOCAN estimates 196,157 new multiple-myeloma cases worldwide in 2024, but high drug expenditure and prolonged treatment make the disease's commercial contribution much larger than incidence alone suggests.
B-cell lymphomas account for an estimated 29%, while leukemias, Hodgkin lymphoma and other hematologic malignancies make up the remaining market.
CD Antigen Cancer Therapy Geographical Analysis
North America Leads with 41.5%
North America is estimated to account for 41.5% of global market revenue in 2025, equal to around USD 12.78 billion.
The legacy DMI page also identifies North America as the largest region, although it contains conflicting 38.4% and 42.4% share statements.
The United States is modeled at 36.4% of global revenue, or around USD 11.21 billion. Its leadership is supported by rapid adoption of CAR-T and bispecific therapies, extensive cell-therapy infrastructure and early regulatory access to new indications.
Recent U.S. approvals include Tecvayli plus Darzalex in March 2026, frontline Darzalex Faspro-VRd in January 2026 and subcutaneous Sarclisa Escena in July 2026.
Europe Accounts for 25.6%
Europe is estimated to hold around 25.6% of 2025 global revenue, USD 7.88 billion.
Germany is modeled at 5.2% of global value, the UK at 4.3%, France at 3.9%, Italy at 2.5% and Spain at 2.2%.
European growth is being supported by wider availability of CD38, CD20-bispecific and CAR-T therapies. Sanofi received European approval in June 2026 for subcutaneous Sarclisa administered by an on-body injector, while several CD20 bispecific and CAR-T platforms continue expanding across lymphoma indications.
Asia-Pacific Is the Fastest-Growing Region
Asia-Pacific is estimated to account for 25.4% of the 2025 market, around USD 7.82 billion, and is expected to grow fastest through 2035.
The underlying patient base is substantial. GLOBOCAN 2024 places 44.5% of global NHL cases and 41.6% of multiple-myeloma cases in Asia, even though the region's commercial revenue share remains far below its share of patients.
China is modeled at 7.5% of global market revenue, Japan at 5.1%, South Korea at 3.0%, India at 2.3% and Australia at 1.6%.
The principal long-term opportunity is closing the gap between disease burden and access to expensive biologics, bispecifics and cell therapies.
Latin America Accounts for 4.2%
Latin America represents 4.2% of 2025 global revenue, equal to roughly USD 1.29 billion.
Brazil is the largest country opportunity at 2.2% of global revenue. Access to monoclonal antibodies is broader than access to CAR-T and newer bispecifics, leaving a meaningful commercial expansion opportunity as specialist hematology infrastructure improves.
Middle East & Africa Represent 3.3%
Middle East & Africa account for an estimated 3.3% of the market, USD 1.02 billion.
Saudi Arabia, the UAE and Israel represent the strongest premium-treatment markets, while South Africa remains an important specialist hematology market.
Cell-therapy infrastructure, reimbursement and high acquisition costs remain the major barriers to broader regional adoption.
CD Antigen Cancer Therapy Competitive Landscape
Johnson & Johnson currently holds the strongest overall commercial position through CD38 and BCMA. DARZALEX generated USD 14.351 billion in 2025, CARVYKTI USD 1.887 billion and TECVAYLI USD 670 million. The March 2026 Tecvayli-Darzalex approval also gives J&J a distinctive two-antigen combination strategy.
Roche/Genentech maintains one of the broadest lymphoma portfolios through CD20 and CD79b, including Rituxan/MabThera, Gazyva, Lunsumio, Columvi and Polivy. Roche reported CHF 1.47 billion in Polivy sales and CHF 288 million in Columvi sales during 2025.
Bristol Myers Squibb is increasingly important in cellular therapy through Breyanzi and Abecma. Breyanzi generated USD 1.4 billion in 2025 revenue and obtained a new marginal-zone-lymphoma indication in December 2025.
Gilead/Kite remains a major CD19 CAR-T competitor through Yescarta and Tecartus, which generated USD 1.5 billion and USD 344 million respectively in 2025.
Genmab/AbbVie is gaining share through CD20×CD3 bispecific EPKINLY. Global EPKINLY/TEPKINLY sales reached USD 468 million in 2025, and the November 2025 follicular-lymphoma combination approval expands the addressable population.
Sanofi competes against the dominant CD38 franchise through Sarclisa and strengthened its differentiation with the 2026 subcutaneous on-body delivery system.
GSK has re-entered the BCMA segment through Blenrep, while Pfizer participates through CD30-targeted Adcetris, CD22-targeted Besponsa, CD33-targeted Mylotarg and BCMA-targeted Elrexfio.
Other relevant companies include Novartis, Incyte, Celltrion and a growing group of biotechnology developers working on multi-target CAR-T and next-generation bispecific antibodies.
Recent CD Antigen Cancer Therapy Market Developments
- July 9, 2026: FDA approved Sarclisa Escena, a subcutaneous anti-CD38 therapy, across multiple-myeloma indications.
- March 5, 2026: FDA approved Tecvayli plus Darzalex Faspro after at least one prior line of therapy in relapsed/refractory multiple myeloma and converted Tecvayli's original monotherapy indication to traditional approval.
- January 27, 2026: FDA approved Darzalex Faspro plus VRd for newly diagnosed multiple myeloma in transplant-ineligible adults.
- December 19, 2025: FDA approved the subcutaneous Lunsumio Velo formulation for relapsed/refractory follicular lymphoma after two or more systemic therapies.
- December 4, 2025: FDA approved Breyanzi for relapsed/refractory marginal zone lymphoma, the first U.S. CAR-T approval for that disease.
- November 18, 2025: FDA approved epcoritamab with lenalidomide and rituximab in relapsed/refractory follicular lymphoma.
- November 6, 2025: FDA approved Darzalex Faspro for high-risk smoldering multiple myeloma, extending CD38 therapy into a pre-active-myeloma setting.
- October 23, 2025: FDA approved Blenrep plus bortezomib and dexamethasone for relapsed/refractory multiple myeloma, re-establishing BCMA ADC treatment in the U.S.
- July 2, 2025: FDA granted accelerated approval to Lynozyfic, a BCMA×CD3 bispecific antibody, after at least four prior therapy lines.
Strategic Opportunity Areas Through 2035
Multi-antigen CAR-T represents one of the clearest pipeline opportunities. Phase III development of CD19/CD20 CAR-T and early studies of CD19/CD20/CD22 constructs are testing whether broader recognition can reduce antigen escape.
Earlier-line bispecific therapy could substantially enlarge the market because commercially successful CD20 and BCMA bispecifics are moving from heavily pretreated disease toward first relapse and combination regimens. The 2026 Tecvayli-Darzalex approval provides the clearest current example.
Outpatient and subcutaneous treatment is another major commercial opportunity. Sarclisa Escena and Lunsumio Velo demonstrate how administration technology can differentiate products even when the underlying antigen target is established.
Post-CAR-T sequencing remains an important unmet need as the treated population expands. Bispecific antibodies, alternate-antigen CAR-T and ADCs may increasingly compete for patients relapsing after first-generation cellular therapy.
Asia-Pacific access provides the largest geographic white space. Asia carries 44.5% of worldwide NHL cases and 41.6% of multiple-myeloma cases but remains substantially underrepresented in global therapy revenue.
Why Choose DataM Intelligence?
- DataM Intelligence's refreshed CD antigen cancer therapy analysis expands the market beyond the legacy CD19/CD20/CD22/CD30 framework to reflect the targets generating today's actual commercial value.
- The report connects CD38 antibodies, CD19 CAR-T, CD20 bispecifics, BCMA/CD269 CAR-T and bispecifics, CD30 and CD79b ADCs, and emerging multi-target cellular therapy within one commercial model.
- It also evaluates a critical strategic change: companies increasingly compete through combinations and sequencing across antigen classes rather than through one target or one therapeutic modality in isolation.
- The report quantifies target, modality, indication and regional opportunities while incorporating current FDA developments through August 2026.
Target Audience
The report is designed for pharmaceutical and biotechnology companies, CAR-T developers, bispecific-antibody companies, ADC developers, hematology-oncology companies, cell-therapy manufacturers, comprehensive cancer centers, hospital systems, specialty pharmacies, contract research organizations, investors, licensing teams, market-access groups and academic hematology programs.
